Prospective cohort studies on immunosurveillance of SARS-CoV-2 in Switzerland
- Funded by State Secretariat for Education, Research, and Innovation SERI (Staatssekretariat für Bildung, Forschung und Innovation)
- Total publications:0 publications
Grant number: 0142005382
Grant search
Key facts
Disease
COVID-19Start & end year
20222023Known Financial Commitments (USD)
$491,809.92Funder
State Secretariat for Education, Research, and Innovation SERI (Staatssekretariat für Bildung, Forschung und Innovation)Principal Investigator
Abteilung Übertragbare Krankheiten Sekretariat derResearch Location
N/ALead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
With the continuation of the twin study, which is already ongoing, until the end of 2023, important information on the immunological status of the Swiss population will be investigated. These findings provide an additional basis based on evidence-based scientific data, which will be used to develop strategies and recommendations as the pandemic progresses and in particular in view of a possible wave of infections in autumn 2022. The two cohort studies "Zurich Coronavirus Cohort Study" (ZSAC) and "Zurich Coronavirus Vaccination Study" (ZVAC) are population-based, prospective cohort studies that observe representative populations of 1552 recovered (ZSAC) and 575 vaccinated people (ZVAC) respectively since the time of infection with SARS-CoV-2 or vaccination. In March 2022, a follow-up of over 18 months for the ZSAC study and a 10-month follow-up resulted...